Cautionary Statement This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in investor presentations, press releases, Securities and Exchange Commission (SEC) filings, and in oral statements made by or with the approval of one of our executive officers, the words or phrases like "expects," "anticipates," "believes," "intends," "likely will result," "estimates," "projects," or variations of such words and similar expression ...

Humana (HUM) 2025 Investor Day Summary Company Overview - **Company**: Humana Inc. (HUM) - **Event**: 2025 Investor Day held on June 16, 2025, in Louisville, Kentucky Key Industry Insights - **Industry Focus**: Senior healthcare services, particularly Medicare Advantage (MA) - **Market Dynamics**: The Medicare Advantage sector is experiencing significant growth, with over 10,000 individuals turning 65 daily, leading to an expected increase in Medicare beneficiaries from 64 million today to 72 million by 2030 [88][90] Core Points and Arguments 1. **Transformation from Insurance to Health Services**: Humana has evolved from primarily a health insurance company to a health services company, with a focus on integrated senior healthcare strategies [19][20] 2. **Medicare Advantage Value Proposition**: - MA delivers superior value and better health outcomes compared to original Medicare [80] - MA reduces out-of-pocket costs for seniors, providing comprehensive benefits such as dental, vision, and pharmacy [83][84] - MA has bipartisan political support, with over half of Medicare beneficiaries enrolled in MA plans [87] 3. **Financial Performance and Growth**: - Humana aims to unlock significant earnings power, currently operating at a fraction of its potential [22] - The company is focused on delivering a stable and compelling Medicare Advantage margin, emphasizing operational efficiency over benefits [68][69] - Humana's enrollment CAGR has been 11%, outpacing the industry average of 9% [98] 4. **Clinical Excellence Strategy**: - The strategy is built on understanding member needs, improving health outcomes, and lowering total care costs [102] - Emphasis on accurate diagnosis, follow-up care, and innovative clinical programs to enhance member engagement and trust [102][103] 5. **Operational Leverage**: - Humana is focused on improving operational efficiency to drive better margins and sustainable growth [40][41] - The company plans to invest in clinical outcomes and lower medical costs while narrowing the gap in operational leverage [41][42] Additional Important Insights - **Challenges and Opportunities**: The current environment presents challenges, but these can also create opportunities for growth and innovation [75][76] - **Future Projections**: Humana anticipates that by 2028, Medicaid and Cinerwell will play a more prominent role in the business, contributing to overall growth [66][68] - **Member Retention Focus**: The company recognizes that retaining existing members is crucial for long-term growth, with service quality being a key factor in retention [51][52] Conclusion - Humana is positioning itself as a leader in the senior healthcare services market, with a strong focus on Medicare Advantage, clinical excellence, and operational efficiency. The company aims to leverage its scale and market presence to drive sustainable growth and deliver better health outcomes for its members while enhancing shareholder value [97][98]

Company Overview - Humana Inc. is a for-profit health insurance company that provides Medicare Advantage, individual and group insurance, pharmacy benefit management, and integrated care services through its CenterWell network [3] Allegations and Legal Issues - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving Humana, stemming from allegations of providing misleading business information to investors [1] - On June 5, 2025, The Wall Street Journal reported that Humana supports congressional efforts to reform Medicare billing practices, which have generated billions in extra payments for the health insurance industry [4] - Humana's support includes restrictions on payments for home-visit diagnoses, which accounted for $15 billion in revenue for Medicare Advantage insurers from 2019 to 2021 [4] - The investigation follows a False Claims Act Complaint filed by the Department of Justice against Humana and other major insurers for allegedly providing kickbacks to insurance brokers for enrolling customers in Medicare Advantage plans between 2016 and 2021 [4] Stock Performance - Following the announcement of the DOJ lawsuit, Humana's stock declined by $6.20 per share, or 2.36%, closing at $256.04 per share on May 1, 2025 [5]

NEWTOWN, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Humana Inc. (“Humana”) (NYSE: HUM), resulting from allegations of providing potentially misleading business information to the investing public. If you have non-public information that could assist in the Humana investigation, or if you are a Humana investor who suffered a loss and would like to learn more, you can provide your information HERE. You can also con ...

Core Insights - The article emphasizes the importance of high-quality dividend investments for safeguarding and growing wealth in various market conditions [2] Group 1: Investment Strategy - The investing group "The Dividend Kings" focuses on helping investors achieve better long-term total returns through dividend stocks [2] - The group provides resources such as 13 model portfolios, buy ideas, and company research reports to assist members in making informed investment decisions [2] Group 2: Analyst Team - The article mentions a team of analysts including Brad Thomas, Justin Law, Nicholas Ward, Chuck Carnevale, and Sebastian Wolf, who contribute to the investment insights provided [2] - The team aims to foster a community for readers to learn and engage in intelligent investing practices [2]

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices involving Humana Inc. and its officers or directors [1] Group 1: Legal Issues - The U.S. Department of Justice filed a False Claims Act complaint against Humana and other health insurance companies, alleging that from 2016 to at least 2021, they paid hundreds of millions of dollars in illegal kickbacks to brokers for enrollments in Medicare Advantage plans [3] - Following the DOJ's lawsuit announcement, Humana's stock price decreased by $6.20 per share, or 2.36%, closing at $256.04 on May 1, 2025 [3] Group 2: Company Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [4]

NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Humana Inc.  (“Humana” or the “Company”) (NYSE: HUM).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Humana and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 1, 2025, the U.S. ...

NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Humana Inc. (“Humana” or the “Company”) (NYSE:HUM). The investigation concerns whether Humana and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] On May 1, 2025, the U.S. Department of Justice filed a complaint against insurance broker organizations, including Humana, alleging t ...

NEW YORK, May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Humana Inc. ("Humana" or the "Company") (NYSE: HUM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Humana and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On May 1, 2025, the U.S. Department of ...

NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Humana Inc. (“Humana” or the “Company”) (NYSE: HUM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Humana and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 1, 2025, the U.S. De ...